Notice of Intent to Sole Source: Lutathera and Pluvicto
Closed Special Notice Posted
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Texas 78234, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Medical Readiness Contracting Office-West published a Special Notice of Intent to Sole Source a contract to Advanced Accelerator Applications USA for the supply of two radiopharmaceuticals. The contracting agency is the Department of the Army Medical Command.
The Special Notice aims to award an indefinite-delivery indefinite-quantity contract on a sole source basis for the supply of Lutetium Lu-177 Dotatate and Lutetium Lu-177 Vipivotide Tetraxetan to meet the needs of the Brooke Army Medical Center Department of Nuclear Medicine. The estimated contract amount is for a base year from 1 October 2023 to 30 September 2024. Any responses must be submitted by 30 August 2023, and verbal responses will not be considered. While the Special Notice is not a solicitation, any vendors who believe they can provide the stated supplies may submit a capability statement for consideration, however Advanced Accelerator Applications USA is identified as the only manufacturer of these pharmaceuticals, which have no generic alternatives available.
Notice text
The Medical Readiness Contracting Office-West insteads to award a sole source contract to Advanced Accelerator Applications USA (AAA), for 2 FDA approved radiopharmaceuticals of which they are the manufacturer.
The Department of Nuclear Medicine Service at Brooke Army Medical Center (BAMC) requires two Food and Drug Administration (FDA) approved products that are required for the imaging and treatment of somatostatin receptor-positive gastroeteropancreatic neuroendocrine tumors and for the treatment of adult patients with prostatic-specific membrane antigen-positive metastatic castration-resistant prostate cancer. The following are description of items and quantities:
Lutetium Lu-177 Dotatate Quantity (Qty) per year: 15
Lutetium Lu-177 Vipivotide Tetraxetan Qty per year: 200
This notice of intent is not a request for quotations and a solicitation will not be issued in conjunction with the notice of intent. Any vendor that believes it can provide the stated supplies may provide a capability statement. Verbal responses are not acceptable and will not be considered.
Files
| File | Type | Posted |
|---|---|---|
| Lutathera and Pluvicto JA__Redacted.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Special Notice | |
| Lutathera and Pluvicto | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--Sources Sought Notice - Ga68 Dotatate (NETSPOT) | Veterans Integrated Service Network 17 | No set-aside | |
| 6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 | Veterans Integrated Service Network 10 | No set-aside | |
| Notice of Award Maintenance for Government owned BacT/ALERT 3D Equipment. | Medical Command | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity